Compare STEL & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEL | ANAB |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2017 |
| Metric | STEL | ANAB |
|---|---|---|
| Price | $31.43 | $43.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $31.33 | ★ $59.90 |
| AVG Volume (30 Days) | 270.3K | ★ 407.6K |
| Earning Date | 01-30-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.94 | N/A |
| Revenue | ★ $416,539,000.00 | $169,467,000.00 |
| Revenue This Year | N/A | $135.45 |
| Revenue Next Year | $3.41 | N/A |
| P/E Ratio | $16.28 | ★ N/A |
| Revenue Growth | N/A | ★ 196.42 |
| 52 Week Low | $24.13 | $12.21 |
| 52 Week High | $32.74 | $52.47 |
| Indicator | STEL | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 45.58 |
| Support Level | $30.09 | $46.89 |
| Resistance Level | $31.66 | $52.47 |
| Average True Range (ATR) | 0.62 | 2.25 |
| MACD | -0.09 | -0.96 |
| Stochastic Oscillator | 48.59 | 16.95 |
Stellar Bancorp Inc is a U.S. based bank holding company. Through its subsidiary, Stellar Bank, the company provides a diversified range of commercial banking services predominantly to small to medium sized businesses, professionals, and individual customers. Its offerings include different types of loans, such as mortgage loans, home equity loans, automobile loans, etc.; deposit products, such as checking accounts, commercial accounts, money market accounts, savings accounts, etc.; and other banking services like mobile banking, debit cards, cash management and wire transfer services, letters of credit, and others.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).